Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun (Q45309210)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun |
scientific article |
Statements
1 reference
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun (English)
1 reference
Roy S Herbst
1 reference
George Blumenschein
1 reference
David H Johnson
1 reference
Eric Mininberg
1 reference
David P Carbone
1 reference
Ted Henderson
1 reference
Edward S Kim
1 reference
Jack J Lee
1 reference
Diane D Liu
1 reference
Mylene T Truong
1 reference
Waun K Hong
1 reference
Hai Tran
1 reference
Anne Tsao
1 reference
Dong Xie
1 reference
David A Ramies
1 reference
Robert Mass
1 reference
Somasekar Seshagiri
1 reference
David A Eberhard
1 reference
Sean K Kelley
1 reference
Alan Sandler
1 reference
7 March 2005
1 reference
1 reference
23
1 reference
11
1 reference
2544-2555
1 reference
Identifiers
1 reference
1 reference